Small molecules, big players: The National Cancer Institute's Initiative for Chemical Genetics

Cancer Research

Volumn 66, Issue 18, 2006, Pages 8935-8942

  Tolliday, Nicola ^a   Clemons, Paul A ^a   Ferraiolo, Paul ^a   Koehler, Angela N ^a   Lewis, Timothy A ^a   Li, Xiaohua ^a   Schreiber, Stuart L ^a,b   Gerhard, Daniela S ^c   Eliasof, Scott ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEFITINIB; IMATINIB; MONASTROL; PACLITAXEL;

CANADA; CANCER CENTER; CANCER RESEARCH; CELL DIVISION; CELL LYSATE; CELL MIGRATION; CELL VIABILITY; CHEMICAL GENETICS; CHEMISTRY; CHEMOLUMINESCENCE; COLORIMETRY; DRUG INDUSTRY; DRUG MARKETING; FLUORESCENCE; HOMEOSTASIS; HUMAN; MEDICAL RESEARCH; METASTASIS; MOLECULAR GENETICS; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SCREENING; TUMOR CELL;

ANTINEOPLASTIC AGENTS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENOMICS; HUMANS; MODELS, MOLECULAR; MOLECULAR PROBES; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; UNITED STATES;

EID: 33749499483     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2552     Document Type: Review

References (36)

1. Schreiber SL. Small molecules: the missing link in the central dogma. Nat Chem Biol 2005;1:64-6.
2. Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci U S A 1999;96:14866-70.
3. Muller O, Gourzoulidou E, Carpintero M, et al. Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening. Angew Chem Int Ed Engl 2004;43:450-4.
4. Schreiber SL. The small-molecule approach to biology: chemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology. Chem Eng News 2003;81:51-61.
5. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94.
6. Hopkins AL, Groom CR The druggable genome. Nat Rev Drug Discov 2002;1:727-30.
7. Stockwell BR. Exploring biology with small organic molecules. Nature 2004;432:846-54.
8. Burke MD, Schreiber SL. A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed Engl 2004;43:46-58.
9. Sauer WH, Schwarz MK. Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J Chem Inf Comput Sci 2003;43:987-1003.
10. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49.
11. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37.
12. MacBeath G, Koehler AN, Schreiber SL. Printing small molecules as microarrays and detecting protein-ligand interactions en masse. J Am Chem Soc 1999;121:7967-8.
13. Bradner JE, McPherson OM, Mazitschek R, et al. A robust small-molecule microarray platform for screening cell lysates. Chem Biol 2006;13:493-504.
14. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ. Multidimensional drug profiling by automated microscopy. Science 2004;306:1194-8.
15. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
16. Shi LM, Fan Y, Lee JK, et al. Mining and visualizing large anticancer drug discovery databases. J Chem Inf Comput Sci 2000;40:367-79.
17. Lampson MA, Kapoor TM. Unraveling cell division mechanisms with small-molecule inhibitors. Nat Chem Biol 2006;2:19-27.
18. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
19. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4.
20. Straight AF, Cheung A, Limouze J, et al. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 2003;299:1743-7.
21. Eggert US, Kiger AA, Richter C, et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol 2004;2:e379.
22. Dai C, Whitesell L. HSP90: a rising star on the horizon of anticancer targets. Future Oncol 2005;1:529-40.
23. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004;40:2217-29.
24. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
25. Verma R, Peters NR, D'Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004;306:117-20.
26. Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, Tortorella D. Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin. Mol Biol Cell 2004;15:1635-46.
27. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28.
28. Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003;9:2882-6.
29. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, Hogan PG. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 2004;101:7554-9.
30. Venkatesh N, Feng Y, DeDecker B, et al. Chemical genetics to identify NFAT inhibitors: potential of targeting calcium mobilization in immunosuppression. Proc Natl Acad Sci U S A 2004;101:8969-74.
31. Schroeder FC, Kau TR, Silver PA, Clardy J. The psammaplysenes, specific inhibitors of FOXO1a nuclear export J Nat Prod 2005;68:574-6.
32. Aznar S, Fernandez-Valeron P, Espina C, Lacal JC. Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 2004;206:181-91.
33. Pelish HE, Peterson JR, Salvarezza SB, et al. Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol 2006;2:39-46.
34. Peterson JR, Bickford LC, Morgan D, et al. Chemical inhibition of N-WASP by stabilization of a native auto-inhibited conformation. Nat Struct Mol Biol 2004;11:747-55.
35. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol 2005;12:385-95.
36. von Eschenbach A. Collaboration to play key role in NCI's future, director says. Interview by Katherine Arnold. J Natl Cancer Inst 2002;94:790-2.